Sarepta join forces with US NIAID to develop influenza drug
Sarepta Therapeutics president and CEO Chris Garabedian said the agreement will lead to development of new treatment options for influenza with new mechanisms of action with limitations of
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.
The collaboration will focus on developing Pfizer biologics, leveraging Halozyme’s drug delivery platform Enhanze technology that is based on the company’s recombinant human hyaluronidase enzyme (rHuPH20). Pfizer BioTherapeutics